SCHEMBL3821159

SCHEMBL3821159

NS(=O)(=O)c1ccc(-c2csc(-c3cnccc3C(F)(F)F)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPC1 O15118 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 3/20 0.43
USP2 O75604 2/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 2/20 0.43
GFER P55789 1/20 0.43
PTGS2 P35354 1/20 0.43
AR P10275 1/20 0.42
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3815028 0.84 KDM4E (0.47) KDM4EMEN1KMT2ANPC1TDP1
SCHEMBL3816401 0.82 CYP19A1 (0.51) KDM4EMEN1KMT2ANPC1NCOA3
SCHEMBL6786537 0.82 KDM4E (0.61) KDM4EMEN1KMT2ANPC1TDP1
SCHEMBL3819669 0.81 KDM4E (0.54) KDM4EMEN1KMT2ANPC1TDP1
SCHEMBL3812816 0.81 HPGD (0.53) KDM4EMEN1KMT2ANPC1TDP1
Hydrochloric Acid SCHEMBL5732874 0.80 HPGD (0.52) KDM4EMEN1KMT2ANPC1TDP1
SCHEMBL3815420 0.80 KDM4E (0.55) KDM4EMEN1KMT2ANPC1TDP1
SCHEMBL6781128 0.79 CDC25A (0.49) KDM4EMEN1KMT2ANPC1TDP1
SCHEMBL3814242 0.77 RAB9A (0.49) KDM4ENPC1TDP1SMN1; SMN2MAPT
SCHEMBL3823493 0.76 RAB9A (0.64) KDM4EMEN1KMT2ANPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP disclosed
US-7067537-B2 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US disclosed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof CYP17A1, CYP21A2, HSD17B1 KDM4E 1126/4885MEN1 2297/4885KMT2A 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.